Breast Cancer Clinical Trial
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Summary
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
View Eligibility Criteria
Eligibility Criteria
Inclusion Criteria:
Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
Adequate bone marrow, kidney and liver function
Performance status of 0 or 1.
Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.
Exclusion Criteria:
Prior treatment targeting ILT3.
Prior treatment targeting LAIR1.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
Submit
There are 9 Locations for this study
See Locations Near You
NGM Clinical Study Site
Austin Texas, 78758, United States
Austin Texas, 78758, United States
How clear is this clinincal trial information?